Bettina E. Hansen mainly focuses on Internal medicine, Gastroenterology, Surgery, Hepatitis B and Immunology. Internal medicine is often connected to Entecavir in her work. Her Gastroenterology research integrates issues from HBsAg, HBeAg and Hepatitis B virus.
Bettina E. Hansen has researched Surgery in several fields, including Odds ratio, Combination therapy, Confidence interval and Primary biliary cirrhosis. Her study focuses on the intersection of Hepatitis B and fields such as Pharmacotherapy with connections in the field of Chemotherapy. The various areas that Bettina E. Hansen examines in her Immunology study include Discontinuation and Genotype.
Her main research concerns Internal medicine, Gastroenterology, Immunology, Liver transplantation and Surgery. Her Internal medicine study frequently draws parallels with other fields, such as HBeAg. Her work carried out in the field of HBeAg brings together such families of science as Lamivudine, Serology and Discontinuation.
Bettina E. Hansen studied Gastroenterology and Chronic hepatitis that intersect with HBEAG POSITIVE. Her Liver transplantation study integrates concerns from other disciplines, such as Survival rate and Liver disease. The study incorporates disciplines such as Interquartile range and Proportional hazards model in addition to Hazard ratio.
Internal medicine, Gastroenterology, Liver transplantation, Hazard ratio and Cohort are her primary areas of study. Her work in the fields of Internal medicine, such as Liver disease, overlaps with other areas such as In patient. Her Gastroenterology research incorporates themes from Entecavir, Hepatocellular carcinoma and Hepatitis B.
Her study on Liver transplantation also encompasses disciplines like
The scientist’s investigation covers issues in Internal medicine, Gastroenterology, Hazard ratio, Liver transplantation and Cohort. Bettina E. Hansen works mostly in the field of Internal medicine, limiting it down to topics relating to HBsAg and, in certain cases, Regimen, as a part of the same area of interest. She combines subjects such as Entecavir, Hepatitis B, HBeAg and Chronic hepatitis with her study of Gastroenterology.
Her Hazard ratio research integrates issues from Fibrosis, Breathing, Interquartile range and Retrospective cohort study. Her Interquartile range research focuses on Proportional hazards model and how it connects with Liver cancer. Her Liver transplantation study also includes
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.
Adriaan J. van der Meer;Bart J. Veldt;Jordan J. Feld;Heiner Wedemeyer.
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial
Harry L A Janssen;Monika van Zonneveld;Hakan Senturk;Stefan Zeuzem.
The Lancet (2005)
Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced Fibrosis
Bart J Veldt;E Jenny Heathcote;Heiner Wedemeyer;Juerg Reichen.
Annals of Internal Medicine (2007)
A Placebo-controlled trial of obeticholic acid in primary biliary cholangitis
F. Nevens;P. Andreone;G. Mazzella;S. I. Strasser.
The New England Journal of Medicine (2016)
Long‐term follow‐up of alpha‐interferon treatment of patients with chronic hepatitis B
Monika van Zonneveld;Pieter Honkoop;Bettina E. Hansen;Hubertus G.M. Niesters.
Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α-2b
Erik H.C.J. Buster;Hajo J. Flink;Yilmaz Cakaloglu;Krzysztof Simon.
Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
Erik H.C.J. Buster;Bettina E. Hansen;George K.K. Lau;Teerha Piratvisuth.
Improved Prognosis of Patients With Primary Biliary Cirrhosis That Have a Biochemical Response to Ursodeoxycholic Acid
Edith M.M. Kuiper;Bettina E. Hansen;Richard A. de Vries;Jannie W. den Ouden–Muller.
Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.
Milan J. Sonneveld;Vincent Rijckborst;Charles A. B. Boucher;Bettina E. Hansen.
Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.
Hajo J. Flink;Monika Van Zonneveld;Bettina E. Hansen;Robert A. De Man.
The American Journal of Gastroenterology (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: